Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U1NA
|
||||
| Former ID |
DIB007892
|
||||
| Drug Name |
Fadolmidine
|
||||
| Synonyms |
Fadolmidine hydrochloride; MPV-2426
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Discontinued in Phase 2 | [1] | ||
| Company |
Orion Corp
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H14N2O
|
||||
| Canonical SMILES |
c12C(Cc3[nH]cnc3)CCc1ccc(c2)O.Cl
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013220) | ||||
| REF 2 | Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev. 2004 Summer;10(2):117-26. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.